Viropharma Inc Watch

from SC TO-C 172 pages Shire Plc as the Company Morgan Stanley Bank International Limited as Mandated Lead Arranger and Bookrunner With Morgan Stanley Bank International Limited as Agent US$ 2,600,000,000 Term Facilities Agreement Dated 11 November 2013 Slaughter and May One Bunhill Row London Ec1y 8yy (Rel/Apxk) 516285245 Contents

from 10-Q 6 pages Viropharma Incorporated Annual Incentive Plan

from 10-K 23 pages First Amendment to Manufacturing and Distribution Agreement

from 10-K 3 pages Confidential Treatment Has Been Requested for Portions of This Exhibit. the Copy Filed Herewith Omits the Information Subject to the Confidentiality Request. Omissions Are Designated as “***”. a Complete Version of This Exhibit Has Been Filed Separately With the Securities and Exchange Commission

from 10-K 11 pages Viropharma Incorporated 2000 Employee Stock Purchase Plan

from 10-Q 17 pages Viropharma Incorporated Amended and Restated 2005 Equity Incentive Plan

from 10-Q 39 pages 2012 Strategic Supply Agreement

from 10-Q 43 pages Amended and Restated Lease for Combination Office/Warehouse at Eagleview Corporate Center 730 Stockton Drive Landlord: 730 Stockton Drive Associates, L.P. and the Hankin Group Tenant: Viropharma Incorporated

from S-8 17 pages Viropharma Incorporated Amended and Restated 2005 Equity Incentive Plan

from 10-Q 1 page Amendment No. 4 to Distribution and Supply Agreement

from 10-Q 1 page Amendment No. 3 to Distribution and Supply Agreement

from 10-Q 2 pages Amendment No. 2 to Distribution and Supply Agreement

from 10-Q 1 page Amendment No. 1 to Distribution and Supply Agreement

from 10-Q 51 pages Distribution and Supply Agreement by and Between Viropharma Incorporated and Prasco, LLC Dated November 30, 2007

from 10-Q 2 pages Re: Third Amendment to That Certain Agreement for the Purchase and Sale of Blood Plasma (The “Purchase Agreement”) Dated July 12, 2007, Between Viropharma Biologics, Inc. (Successor in Interest to Lev Pharmaceuticals, Inc.) (“Purchaser”) and DCI Management Group LLC (“Seller”), as Amended by That Certain First Amendment Dated July 9, 2009 and Second Amendment Dated February 5, 2010 (As Amended, the “Purchase Agreement”) Any Capitalized Terms Used in This Letter (This “Third Amendment”) That Are Not Otherwise Defined Herein Shall Have the Meanings Assigned to Such Terms in the Purchase Agreement. Each of the Parties to This Third Amendment (Each, a “Party,” And, Collectively, the “Parties”) Hereby Acknowledges, Consents To, and Ratifies the Following Actions and Amendments

from 10-K/A 185 pages Development and Option Agreement Dated as of December 22, 2011 by and Between Viropharma Incorporated and Meritage Pharma, Inc

from 10-Q 3 pages Amendment to the Intermediate Supply Agreement of 1 June 2009

from 10-K 64 pages Development and Option Agreement Dated as of December 22, 2011 by and Between Viropharma Incorporated and Meritage Pharma, Inc

from 10-K 32 pages Share Purchase Agreement Relating to the Sale and Purchase of All Shares in Duocort Pharma Ab Between Duocort Ab (As the Seller) and Goldcup 6975 Ab

from 10-K 2 pages Amendment No. 2 to Exclusive Clinical Study and Data License Agreement Between Genzyme Corporation and Viropharma Incorporated